Palvella Therapeutics (PVLA) Cash & Equivalents (2013 - 2026)
Palvella Therapeutics (PVLA) reported Cash & Equivalents of $206.4 million for Q1 2026, up 172.91% year-over-year from $75.6 million in Q1 2025, and up 255.96% on a QoQ basis from $58.0 million in Q4 2025.
Palvella Therapeutics (PVLA) has 14 years of Cash & Equivalents data on file, last reported at $206.4 million in Q1 2026.
- Quarterly Cash & Equivalents rose 172.91% year-over-year to $206.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $206.4 million (up 172.91% YoY) and the FY2025 annual result came in at $58.0 million, down 30.65% from the prior year.
- Cash & Equivalents advanced to $206.4 million in Q1 2026 per PVLA's latest filing, from $58.0 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $206.4 million in Q1 2026 and bottomed at $6.2 million in Q1 2024.
- The 5-year median for Cash & Equivalents is $54.3 million (2022), against an average of $56.7 million.
- The widest annual swing landed in 2024, when Cash & Equivalents slumped 84.28%; it then surged 1110.4% in 2025.
- Tracing PVLA's Cash & Equivalents over 5 years: stood at $38.6 million in 2022, then slumped by 80.98% to $7.4 million in 2023, then surged by 1037.44% to $83.6 million in 2024, then tumbled by 30.65% to $58.0 million in 2025, then jumped by 255.96% to $206.4 million in 2026.
- Per Business Quant, the three latest PVLA Cash & Equivalents figures stand at $206.4 million (Q1 2026), $58.0 million (Q4 2025), and $63.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 1.91 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.49 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.96 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.71 Bn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | 206.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 206.39 Mn |
| Dec 31, 2025 | 57.98 Mn |
| Sep 30, 2025 | 63.57 Mn |
| Jun 30, 2025 | 70.43 Mn |
| Mar 31, 2025 | 75.63 Mn |
| Dec 31, 2024 | 83.60 Mn |
| Sep 30, 2024 | 14.21 Mn |
| Jun 30, 2024 | 14.54 Mn |
| Mar 31, 2024 | 6.25 Mn |
| Dec 31, 2023 | 7.35 Mn |
| Sep 30, 2023 | 44.80 Mn |
| Jun 30, 2023 | 54.90 Mn |
| Mar 31, 2023 | 39.74 Mn |
| Dec 31, 2022 | 38.64 Mn |
| Sep 30, 2022 | 48.42 Mn |
| Jun 30, 2022 | 54.26 Mn |
| Mar 31, 2022 | 83.74 Mn |
| Dec 31, 2021 | 117.76 Mn |
| Sep 30, 2021 | 34.90 Mn |
| Jun 30, 2021 | 91.80 Mn |
| Mar 31, 2021 | 66.84 Mn |
| Dec 31, 2020 | 70.44 Mn |
| Sep 30, 2020 | 66.89 Mn |
| Jun 30, 2020 | 44.30 Mn |
| Mar 31, 2020 | 47.43 Mn |
| Dec 31, 2019 | 62.26 Mn |
| Sep 30, 2019 | 46.07 Mn |
| Jun 30, 2019 | 54.90 Mn |
| Mar 31, 2019 | 52.09 Mn |
| Dec 31, 2018 | 71.94 Mn |
| Sep 30, 2018 | 89.48 Mn |
| Jun 30, 2018 | 50.58 Mn |
| Mar 31, 2018 | 109.52 Mn |
| Dec 31, 2017 | 37.88 Mn |
| Sep 30, 2017 | 89.92 Mn |
| Jun 30, 2017 | 50.32 Mn |
| Mar 31, 2017 | 55.24 Mn |
| Dec 31, 2016 | 29.36 Mn |
| Sep 30, 2016 | 36.56 Mn |
| Jun 30, 2016 | 40.37 Mn |
| Mar 31, 2016 | 31.19 Mn |
| Dec 31, 2015 | 29.35 Mn |
| Sep 30, 2015 | 32.25 Mn |
| Jun 30, 2015 | 10.03 Mn |
| Mar 31, 2015 | 13.17 Mn |
| Dec 31, 2014 | 18.47 Mn |
| Sep 30, 2014 | 936,183.00 |
| Jun 30, 2014 | 1.49 Mn |
| Mar 31, 2014 | 3.27 Mn |
| Dec 31, 2013 | 3.69 Mn |
| Sep 30, 2013 | 688.00 |
| Jun 30, 2013 | 5,200.00 |